Latest News

New failed trials of intrathecal rituximab in PMS


The limited benefit of B cell-directed therapies in progressive MS has been attributed in part to poor penetration of the CNS by monoclonal antibodies. However, two new studies have reported that intrathecal administration of rituximab has little effect on CNS inflammation, suggesting that limited drug entry into the brain is not the main problem. Read More


T25FW useful to identify early progression in MS


A new analysis has reported that significant worsening on the Timed 25-Foot Walk (T25FW) is predictive of EDSS progression in a majority of MS cases (Kalinowski et al. Mult Scler 2021; epublished June 8, 2021). Confirmed disability progression (CDP) was defined as >20% change from baseline in T25FW sustained for >90 days. Read More